Medicines recall

Xaggitin XL 18 mg Prolonged-release Tablets

Issued on 20 Jul 2026 · source: MHRA — Medicines and Healthcare products Regulatory Agency

Affected batches: 183155 (30/10/2027), 185442 (31/12/2027), 174975 (31/05/2027), 175037 (31/05/2027), 178223 (31/07/2027), 183931 (30/11/2027), 185438 (30/11/2027), 185439 (30/11/2027), 185440 (30/11/2027), 187560 (28/02/2028), 175426 (30/06/2027), 175428 (30/06/2027), 176698 (30/06/2027), 176699 (30/06/2027), 176700 (30/06/2027), 182875 (30/09/2027), 183003 (31/10/2027), 178338 (31/07/2027), 178432 (31/07/2027), 178481 (31/07/2027), 180343 (30/09/2027), 187926 (28/02/2028), 187927 (28/02/2028), 187928 (28/02/2028), 187929 (28/02/2028), 187930 (28/02/2028)

Check the batch number on the pack. The medicine remains licensed; other batches are not affected.

Class 4 defect notification · 4 products · DMRC- 39567957 · PL: 01883/0359 · licence holder: Macarthys Laboratories Ltd Trading as Martindale Pharma · active ingredient: methylphenidate hydrochloride · licence PL: 01883/0359

MHRA alert on GOV.UK ↗ All events: Xaggitin XL 18 mg Prolonged-release Tablets

What this means

The MHRA has issued a medicines recall or defect notification. Class 1: risk to life, immediate recall. Class 2: may cause mistreatment or harm, recall within 48 hours. Class 3: unlikely to cause harm, recall within 5 days. Class 4 (defect notification): no recall, caution in use. The medicine remains licensed; only the listed batches are affected. Do not stop treatment without speaking to your doctor or pharmacist.

Class 4 defect notification · DMRC- 39567957

Product	Licence	Active ingredient	GTIN
Xaggitin XL 18 mg Prolonged-release Tablets	PL: 01883/0359	methylphenidate hydrochloride	05060078672023
Xaggitin XL 27 mg Prolonged-release Tablets	PL: 01883/0360	methylphenidate hydrochloride	05060078670227
Xaggitin XL 36 mg Prolonged-release Tablets	PL: 01883/0361	methylphenidate hydrochloride	05060078672030
Xaggitin XL 54 mg Prolonged-release Tablets	PL: 01883/0362	methylphenidate hydrochloride	05060078672047

Batches (expiry): 183155 (30/10/2027), 185442 (31/12/2027), 174975 (31/05/2027), 175037 (31/05/2027), 178223 (31/07/2027), 183931 (30/11/2027), 185438 (30/11/2027), 185439 (30/11/2027), 185440 (30/11/2027), 187560 (28/02/2028), 175426 (30/06/2027), 175428 (30/06/2027), 176698 (30/06/2027), 176699 (30/06/2027), 176700 (30/06/2027), 182875 (30/09/2027), 183003 (31/10/2027), 178338 (31/07/2027), 178432 (31/07/2027), 178481 (31/07/2027), 180343 (30/09/2027), 187926 (28/02/2028), 187927 (28/02/2028), 187928 (28/02/2028), 187929 (28/02/2028), 187930 (28/02/2028)

Background: Macarthys Laboratories Ltd T/A Martindale Pharma has notified the MHRA of a manufacturing issue impacting several batches of Xaggitin XL Prolonged-release Tablets, due to the occurrence of incorrect tablet counts in the bottles. Multiple complaints of incorrect quantities of tablets in packs of Xaggitin XL Prolonged-release Tablets have been received. The majority of reports are for missing tablets but extra tablets have also been reported. The batches listed as ‘not yet distributed’ may be impacted by the same issue. The MHRA, in discussion with the Department of Health and Social Care, considers these products critical for patients, therefore these batches will not be repackaged and continue to be distributed. They are therefore included in the notification. The defect appears to be impacting a low percentage of packs within a batch, impacting reconciliation of the Schedule 2 Contr

Tracked from information published by the MHRA and the NHSBSA. This information is for guidance only and does not replace advice from your doctor or pharmacist.